The objective of this study was to investigate whether changes in A beta and ERAB exist in the brain of diabetic mice, and to observe the effects of APP17 peptide. The numbers of neurons stained by APP17 peptide A beta1-40 A beta1-42 A beta1-16 and ERAB antibodies in the brain of diabetic mice was increased compared with normal mice. Staining in APP17 peptide-protected mice was similar to normal mice. We conclude that increased A beta1-42 and ERAB is an important cause of neuronal degeneration in diabetic encephalopathy. APP17 peptide retards neuronal degeneration by regulating the metabolism of A beta. NeuroReport 12:3317-3319 (C) 2001 Lippincott Williams & Wilkins.
第一作者机构：[1]Beijing Research Laboratory for Brain Aging, Xuanwu Hospital, Capital University of Medical Sciences, Beijing 100053, China
通讯作者：
通讯机构：[1]Beijing Research Laboratory for Brain Aging, Xuanwu Hospital, Capital University of Medical Sciences, Beijing 100053, China
推荐引用方式(GB/T 7714)：
Sheng Shuli,Zhao Yongmei,Zhao Zhiwei,et al.beta-amyloid and its binding protein in the hippocampus of diabetic mice: effect of APP17 peptide[J].NEUROREPORT.2001,12(15):3317-3319.doi:10.1097/00001756-200110290-00034.
APA：
Sheng Shuli,Zhao Yongmei,Zhao Zhiwei&Ji Zhijuan.(2001).beta-amyloid and its binding protein in the hippocampus of diabetic mice: effect of APP17 peptide.NEUROREPORT,12,(15)
MLA：
Sheng Shuli,et al."beta-amyloid and its binding protein in the hippocampus of diabetic mice: effect of APP17 peptide".NEUROREPORT 12..15(2001):3317-3319
